Acquired Company
Aquinox Pharmaceuticals completed the merger with Neoleukin Therapeutics, Inc. and the combined company began trading under the ticker NLTX on August 12, 2019.
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. Show more
Start AI Chat
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$17.64
Open
$17.75
Volume
90,936
Day Range
$17.60 - $19.11
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
09/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
NL-201 (IL-2 and IL-15 agonist) Details Solid tumor/s, Cancer | Failed Discontinued |